Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RGS4 | P49798 | 1/20 | 0.31 |
| ▸ | RGS8 | P57771 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449153 | 0.77 | POLB (0.32) | POLB | |
| SCHEMBL8272853 | 0.68 | — | — | |
| SCHEMBL762381 | 0.67 | — | — | |
| SCHEMBL19542911 | 0.66 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL19543109 | 0.66 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL19542885 | 0.66 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL13698413 | 0.66 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL19542898 | 0.66 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL19543141 | 0.66 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL19542913 | 0.66 | POLB (0.40) | POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | POLB 3563/4885RGS4 759/4885RGS8 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.